CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03879694
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:28.965238+00:00
Published At: 2026-02-06T00:00:00+00:00
Record Updated At: 2026-02-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lung Atypical Carcinoid Tumor", "Lung Typical Carcinoid Tumor", "Metastatic Pancreatic Neuroendocrine Tumor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-06"
protocolSection.identificationModule.nctId: "NCT03879694"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients With Metastatic Neuroendocrine Tumors (NETs)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.